Bazlitoran

N/A

Report date: 2023/06/01 20:00:46
NME

Base Information

Drug NameBazlitoran
Drug Alias NameBazlitoran-sodiumIMO-8400
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionToll like receptor 7 antagonistsToll like receptor 8 antagonistsToll like receptor 9 antagonists
TargetsToll like receptor 8Toll like receptor 9Toll like receptor 7
Therapy Area/IndicationsPlaque psoriasisDermatomyositisWaldenstrom Macroglobulinemia +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesNetherlandsHungary +[4] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIdera
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAceragen Inc
Active IndicationsN/A
Inactive IndicationsPlaque psoriasisDermatomyositisWaldenstrom Macroglobulinemia +[4] 

Other Information

ATC CodeN/A
Related LinksN/A